CIN: L15142RJ1991PLC006353

SARDA PROTEINS LTD.

Date: 30th April 2026

To,
The Corporate Relationship Department
The Bombay Stock Exchange Limited,
P. J. Towers, Dalal Street, Fort,
Mumbai – 400 001

Dear Sir/Madam,

Subject: Outcome of Board Meeting - Results:
Ref: Regulation 30 of SEBI (LODR) Regulations, 2015
OURSELVES: Scrip Code: 519242 ISIN: INE995U01011

Please note that that the meeting of the Board of Directors of the Company was held today on 30th April 2026 at 3.15 pm. The Board of Directors considered and approved the audited financial results for the quarter and financial year ended on 31st March 2026.

We herewith attach the standalone audited financial results along with Cash Flow Statement, Assets Liabilities Statement and Audit Report issued by the Statutory Auditor of the Company and Declaration signed by the Managing Director with respect to unmodified opinion on standalone audited financial results for the financial year ended on 31st March 2026.

The meeting was concluded at 4.15 pm on the same day.

Kindly take note of the same.

With regards

For, Sarda Proteins Limited

Thumar Chirag

Digital Signer:Thumar Chirag
DN:CN=Thumar Chirag,
SERIALNUMBER=33a5b651f01c07dad8774a48507e207c6367fc4ff91e4cf0d8d3af9ff82d0309,
S=Gujarat, PostalCode=360370,
Phone=d1078da587a31e1348f5b923747e6c0a71edaab39adf6a289f67ee32586c3b17,
OID.2.5.4.65=3eoyz5fdi14lga7btw0px8s629vjhcrk,
T=0456, O=Personal, C=IN
Date:30-04-2026 15:58:34 +05:30

Chirag Thummar
Managing Director
DIN: 10640822

Reg. Office: B-536-537, Matsya Industrial Area, Alwar- 301030 (Rajasthan)
Corp. office: Inside Data Ingenious Global Limited, Station Road, Durgapura, Jaipur-302018 (Rajasthan)
Contact No.: +91-7737822222; **E Mail:** sardaproteins@yahoo.com; **Web:** www.sardaproteins.com

SARDA PROTEINS LTD

CIN: L15142RJ1991PLC006353

Reg Off: B-536-537, Matsya Industrial Area, Alwar-301030 (Rajasthan)

EMail: sardaproteins@yahoo.com, website: www.sardaproteins.com

STATEMENT OF STANDALONE AUDITED FINANCIAL RESULTS FOR THE QUARTER AND FINANCIAL YEAR ENDED 31st March, 2026

Rs.in Lakhs

	Particulars	Quarter Ended on			Half Year ended on	Year Ended	
		31.03.2026	31.12.2025	31.03.2025	30.09.2025	31.03.2026	31.03.2025
		Audited	Un-Audited	Audited	Un-Audited	Audited	Audited
I.	Revenue from operations	65.00	25.00	-	1,525.85	1,615.84	2,419.10
II.	Other Income	24.31	-	-	10.62	34.85	0.06
III.	**Total Revenue (I+II)**	**89.31**	**25.00**	**-**	**1,536.47**	**1,650.69**	**2,419.17**
IV.	Expenses:						
	Cost of Material Consumed	-	-	-	-		-
	Purchase of Stock -in- Trade	-	32.17	-	1,515.66	1,547.83	2,391.07
	Changes in Inventories (Finished Goods, WIP, Stock-in-Trade)	-	-	-	-	-	-
	Employee Benefit Expenses	1.00	0.53	0.77	1.50	3.00	8.94
	Finance Cost	-	-	-	-	-	-
	Depreciation and Amoritsation Expenses	-	-	-	-	0.05	-
	Other expenses	3.83	4.11	8.95	28.18	36.01	17.15
	Total Expenses (IV)	**4.83**	**36.81**	**9.72**	**1,545.34**	**1,586.89**	**2,417.16**
V.	Profit/(Loss) before Exceptional and Extraordinary Items and Tax (III-IV)	84.49	(11.81)	(9.72)	(8.88)	63.79	2.01
VI.	Exceptional Items	-	-	-	-	-	-
VII.	Profit/(Loss) before Extraordinary Items and Tax (V-VI)	**84.49**	**(11.81)**	**(9.72)**	**(8.88)**	**63.79**	**2.01**
VIII.	Extraordinary Items	-	-	-	-	-	-
IX.	Profit/(Loss) before Tax (V-VI)	**84.49**	**(11.81)**	**(9.72)**	**(8.88)**	**63.79**	**2.01**
X.	Tax Expense:						
	(1) Current Tax	-	-	-	-	-	-
	(2) Deferred Tax	-	-	1.51	-	-	1.51
XI.	Profit/(Loss) for the period from Continuing Operations (VII-VIII)	**84.49**	**(11.81)**	**(11.23)**	**(8.88)**	**63.79**	**0.50**
XII.	Profit/(Loss) from Discontinued Operations	-	-	-	-	-	-
XIII.	Tax Expenses of Discontinued Operations	-	-	-	-	-	-
XIV.	Profit/(Loss) from Discontinued Operations (after tax) (X-XI)	-	-	-	-	-	-
XV.	Profit/(Loss) for the period (IX+XII)	**84.49**	**(11.81)**	**(11.23)**	**(8.88)**	**63.79**	**0.50**

SARDA PROTEINS LTD
CIN: L15142RJ1991PLC006353
Reg Off: B-536-537, Matsya Industrial Area, Alwar-301030 (Rajasthan)
EMail: sardaproteins@yahoo.com, website: www.sardaproteins.com

STATEMENT OF STANDALONE AUDITED FINANCIAL RESULTS FOR THE QUARTER AND FINANCIAL YEAR ENDED 31st March, 2026

Rs.in Lakhs

	Particulars	**Quarter Ended on**			**Half Year ended on**	**Year Ended**	
		31.03.2026	**31.12.2025**	**31.03.2025**	**30.09.2025**	**31.03.2026**	**31.03.2025**
		Audited	**Un-Audited**	**Audited**	**Un-Audited**	**Audited**	**Audited**
XVI.	Other Comprehensive Income						
	A (i) Items will not be reclassified to Profit or Loss	-	-	-	-	-	-
	(ii) Income Tax relating to items that will not be reclassified to Profit or Loss	-	-	-	-	-	-
	B (i) Items will be reclassified to Profit or Loss	-	-	-	-	-	-
	(ii) Income Tax relating to items that will be reclassified to Profit or Loss	-	-	-	-	-	-
XVII.	**Total Comprehensive Income for the period (XIII+XIV)(Comprising Profit (Loss) and other comprehensive income for the period)**	**84.49**	**(11.81)**	**(11.23)**	**(8.88)**	**63.79**	**0.50**
	Paid up Equity Share Capital (Face Value of the Share-Rs. 10 Per Share)	17.259	17.259	17.259	17.259	17.259	17.259
XVIII	Earnings per Equity Share						
	(1) Basic	4.90	(0.68)	(0.65)	(0.51)	3.70	0.03
	(2) Diluted	4.90	(0.68)	(0.65)	(0.51)	3.70	0.03

On behalf of the Board
For, Sarda Proteins Limited

Date :- 30.04.2026
Place :- Rajasthan

Chirag Thummar
Managing Director
DIN: 10640822

Thumar Chirag

Digitally signed by Thumar Chirag
Date: 2026.04.30 16:00:50 +05'30'

SARDA PROTEINS LTD			
CIN: L15142RJ1991PLC006353			
Reg Off: B-536-537, Matsya Industrial Area, Alwar-301030 (Rajasthan)			
EMail: sardaproteins@yahoo.com, website: www.sardaproteins.com			
BALANCE SHEET AS ON 31st March, 2026			
			(Amount in Lakhs)
Sr. No.	Particulars	As at 31.03.2026 (In Rs.)	As at 31.03.2025 (In Rs.)
		(Audited)	(Audited)
I.	ASSETS		
1	Non-current assets	12.98	12.04
	Total Non-Current Asset	12.98	12.04
2	Current assets		
	(a) Inventory	-	-
	(b) Financial Asset	-	-
	(i) Investment	-	-
	(ii) Trade Receivable	426.54	-
	(iii) Cash and Cash equivalent	750.97	3.38
	(iv) Bank Balance other than (iii) above	-	-
	(v) Loan	-	-
	(vi) Others (Advances)	7,463.14	249.39
	(c) Current Tax Assets (Net)	-	-
	(d) Other Current Asset	7.42	-
	Total Current Asset	8,648.07	252.77
	TOTAL ASSET	8,661.06	264.81
II.	EQUITY AND LIABILITIES		
A	Equity		
	(a) Share Capital	250.45	250.45
	(b) Reserves and Surplus	51.15	(12.65)
	Total Equity	301.60	237.80
B	Liabilities		
1	Non-Current Liabilities		
	(a) Financial Liabilities	-	2.50
	(i) Borrowings	-	-
	(c) Deferred tax liabilities / Asset	-	-
	(d) Othe Non-Current Liabilities	-	-
	Total Non-Current Liabilities	-	2.50
2	Current Liabilities		
	(a) Financial liabilities		1.63
	(i) Borrowings	15.50	-
	(ii) Trade payables	3.36	22.41
	(A) total outstanding dues of micro enterprises and small enterprises	-	-
	(B) total outstanding dues of Creditors other than micro enterprises and small enterprises	-	-
	(b) Other Current Liabilities	-	-
	(i) Duty and Taxes	2.39	
	(ii) Advance against Equity	8,337.50	
	(c) Provisions	0.71	0.47
	(d) Current Tax Liabilities (Net)	-	-
	Total Current Liabilities	8,359.46	24.51
	TOTAL EQUITY AND LIABILITIES	8,661.06	264.81

Notes :-

1. The above results were approved by Audit Committee and by Board of Directors in their meeting held on 30th April 2026
2. The above stated results have been prepared in accordance with the recognition and measurement principles of applicable Indian Accounting Standards and notified under Companies (Indian Accounting Standards) Rules, 2015 (as amended), specified under Section 133 of Companies Act,
3. Segment Results as per AS is not applicable as dealing in only one segment i.e. "Renewable Energy Sector Solar Module Products".
4. No Investor Complaints were received during the quarter ended 31-Mar-2026 nor any pending as on 31.03.2026
5. Figures for the previous period have been regrouped wherever considered necessary so as to confirm to the classification of the current period and to make them comparable.

On behalf of the Board
For, Sarda Proteins Limited

Thumar Chirag
Digitally signed by Thumar Chirag
Date: 2026.04.30 16:01:17 +05'30'

Date :- 30.04.2026
Place :- Rajasthan

Chirag Thummar
Managing Director
DIN: 10640822

SARDA PROTEINS LTD

CIN: L15142RJ1991PLC006353

Reg Off: B-536-537, Matsya Industrial Area, Alwar-301030 (Rajasthan)

EMail: sardaproteins@yahoo.com, website: www.sardaproteins.com

STANDALONE CASH FLOW STATEMENT FOR THE YEAR ENDED ON 31st March, 2026

		(Rs. In Lakhs)
Particulars	**For Year Ended on 31.03.2026**	**For Year Ended on 31.03.2025**
A. CASH FLOW FROM OPERATING ACTIVITIES		
Net profit before tax and extraordinary items	63.79	2.02
Adjustments for:		
Depreciation and amortisation expenses	0.05	-
Finance costs	-	-
Gratuity provision	-	-
Kasar vatav	-	-
Rent income	-	-
Dividend income	-	-
Interest income	(34.85)	(0.06)
Interest on income-tax refund	-	-
Excess income-tax provision written back	-	-
Excess provision for gratuity written back	-	-
Surplus / loss on sale of property, plant and equipment	-	(0.01)
Operating profit before working capital changes	**28.99**	**1.96**
Adjustments for:		-
Increase / (decrease) in trade and other receivables	(7,648.66)	(31.34)
Increase / (decrease) in inventories	-	-
Increase/(decrease) in trade payables, other liabilities and provis	(19.19)	22.20
Other Non Current Liabilities	-	(3.88)
Cash generated from operations	**(7,638.85)**	**(11.07)**
Taxes paid	-	-
Cash flow before extraordinary items	(7,638.85)	(11.07)
Extraordinary items	-	-
Net cash flow from / (used in) operating activities	**(7,638.85)**	**(11.07)**
B. CASH FLOW FROM INVESTING ACTIVITIES		
Sale of property, plant and equipment	-	0.01
Purchase of property, plant and equipment	1.09	-
Purchase of investments	-	-
Interest income	34.85	0.06
Dividend income	-	-
Net cash used in investing activities	35.94	0.07
C. CASH FLOW FROM FINANCING ACTIVITIES		
Proceeds from issue of share capital	0.00	-
Dividend paid (including dividend distribution tax)	-	-
Proceeds for Advance receipt against Equity	8,337.50	-
Proceeds from long-term borrowings	-	2.50
Proceeds from short-term borrowings (net)	-	-
Interest & other borrowing costs	13.00	-
Interest received from others	-	-
Net cash used in financing activities	8,350.50	2.50
NET INCREASE IN CASH AND CASH EQUIVALENTS (A+B+C)	747.59	(8.50)
Cash and cash equivalents as at beginning (Opening balance)	3.38	11.87
Cash and cash equivalents as at end of the year (Closing balance)	750.97	3.38
Net increase/ decrease	**747.59**	**(8.49)**

On behalf of the Board
For, Sarda Proteins Limited

Date :- 30.04.2026
Place :- Rajasthan

Chirag Thummar
Managing Director
DIN: 10640822

Thumar Chirag
Digitally signed by Thumar Chirag
Date: 2026.04.30 16:01:38 +05'30'

INDEPENDENT AUDITOR'S REPORT

Independent Auditor's Report on the Quarterly and Year to Date Standalone Financial Results of SARDA PROTEINS LTD Pursuant to the requirements of Regulation 33 the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended

To the board of directors of
SARDA PROTEINS LIMITED
Report on the audit of the Standalone Financial Results

Opinion

We have audited the accompanying statement of quarterly and year to date standalone financial results of SARDA PROTEINS LIMITED (the "Company") for the quarter ended March 31, 2026 and for the year ended March 31, 2026 ("Statement"), attached herewith, being submitted by the Company pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended.

In our opinion and to the best of our information and according to the explanations given to us, the Statement:

a. gives a true and fair view in conformity with the Indian Accounting Standards prescribed under section 133 of the Act read with the Companies (Indian accounting Standards) Rules, 2015, as amended, ("Ind AS") and other accounting principles generally accepted in India, of the Net Profit for the quarter and year ended March 31, 2026, other comprehensive income and other state of the affairs of the Company for the quarter ended March 31, 2026 and for the year ended March 31, 2026.

Basis for Opinion

We conducted our audit in accordance with the Standards on Auditing (SAs) specified under section 143(10) of the Companies Act, 2013, as amended ('the Act"). Our responsibilities under those Standards are further described in the "Auditor's Responsibilities for the Audit of the Standalone Financial Results" section of our report. We are independent of the Company in accordance with the Code of Ethics issued by the Institute of Chartered Accountants of India together with the ethical requirements that are relevant to our audit of the financial statements under the provisions of the Act and the Rules thereunder, and we have fulfilled our other ethical responsibilities in accordance with these requirements and the Code of Ethics. We believe that the audit evidence obtained by us is sufficient and appropriate to provide a basis for our opinion.

Management's Responsibilities

The Statement has been prepared on the basis of the standalone annual financial statements. The Board of Directors of the Company are responsible for the preparation and presentation of the Statement that gives a true and fair view of the Net Profit, other comprehensive income of the Company and other financial information in accordance with the applicable accounting standards prescribed under section 133 of the Act read with relevant rules issued thereunder and other accounting principles generally accepted in India and in compliance with Regulation 33 of the Listing Regulations.

This responsibility also includes maintenance of adequate accounting records in accordance with the provisions of the Act for safeguarding of the assets of the Company and for preventing and detecting frauds and other irregularities; selection and application of appropriate accounting policies; making judgments and estimates that are reasonable and prudent; and the design, implementation and maintenance of adequate internal financial controls, that were operating effectively for ensuring the accuracy and completeness of the accounting records, relevant to the preparation and presentation of the Statement that give a true and fair view and are free from material misstatement, whether due to fraud or error.

In preparing the Statement, the Board of Directors are responsible for assessing the Company's ability to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless the Board of Directors either intends to liquidate the Company or to cease operations, or has no realistic alternative but to do so.

The Board of Directors are also responsible for overseeing the Company's financial reporting process.

Auditor's Responsibilities

Our objectives are to obtain reasonable assurance about whether the Statement is free from material misstatement. whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance but is not a guarantee that an audit conducted in accordance with SAs will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of the Statement.

As part of an audit in accordance with SAs, we exercise professional judgment and maintain professional skepticism throughout the audit. We also:

- Identify and assess the risks of material misstatement of the Statement, whether due to fraud or error, design and perform audit procedures responsive to those risks, and obtain audit evidence that is sufficient and appropriate to provide a basis for our opinion. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control.

- Obtain an understanding of internal control relevant to the audit in order to design audit procedures that are appropriate in the circumstances. Under Section 143(3)(i) of the Act, we are also responsible for expressing our opinion on whether the Company has adequate internal financial controls with reference to financial statements in place and the operating effectiveness of such controls.

- Evaluate the appropriateness of accounting policies used and the reasonableness of accounting estimates and related disclosures made by the Board of Directors.

- Conclude on the appropriateness of the Board of Directors' use of the going concern basis of accounting and, based on the audit evidence obtained, whether a material uncertainty exists related to events or conditions that may cast significant doubt on the Company's ability to continue as a going concern. If we conclude that a material uncertainty exists, we are required to draw attention in our auditor's report to the related disclosures in the financial results or, if such disclosures are in adequate, to modify our opinion. Our conclusions are based on the audit evidence obtained up to the date of our auditor's report. However, future events or conditions may cause the Company to cease to continue as a going concern.

- Evaluate the overall presentation, structure and content of the Statement, including the disclosures, and whether the Statement represents the underlying transactions and events in a manner that achieves fair presentation.

- Obtain sufficient appropriate audit evidence regarding the standalone financial results of the Company to express an opinion on the standalone financial results.

Other Matter

The Company received Rs. 8337.50 Lakhs as Advance Against Equity Share but the allotment is pending. The Statement includes the results for the quarter ended March 31, 2026 being the balancing figure between the audited figures in respect of the full financial year ended March 31, 2026 and the published unaudited year-to-date figures up to the third quarter of the current financial year, which were subjected to a limited review by us, as required under the Listing Regulations.

For, A H Mandaliya & Associates
CHARTERED ACCOUNTANTS
FRN: 146705W

HIREN J MANDALIYA
Digitally signed by HIREN J MANDALIYA
Date: 2026.04.30 16:16:55 +05'30'

(Hiren J. Mandaliya)
Partner
Mem. No. :- 140193
UDIN :- 26140193KMTCWU5576

Date :- 30.04.2026
Place :- Ahmedabad

CIN: L15142RJ1991PLC006353

SARDA PROTEINS LTD.

To, Date: 30th April 2026

The Corporate Relationship Department
The Bombay Stock Exchange Limited,
P. J. Towers, Dalal Street, Fort,
Mumbai – 400 001

Dear Sir/Madam,

Subject: Declaration of Unmodified opinion on Audited Financial Results for the financial year ended on 31st March 2026

Pursuant to Regulation 33(3)(d) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 as amended from time to time, I, the undersigned, Managing Director of the Company do herewith state and declare that M/s. A. H. Mandaliya & Associates, Statutory Auditors of the Company have issued an unmodified Audit Report on the standalone Audited Financial Results of the Company, for the financial year ended on 31st March 2026.

Request you to please take the same on your record.

For, Sarda Proteins Limited

Thumar
Chirag

Digital Signer:Thumar Chirag
DN:CN=Thumar Chirag,
SERIALNUMBER=33a5b651f01c07dad8774a48507e207c6367fc4ff91e4cf0d8d3af9ff82d0309, S=Gujarat, PostalCode=360370,
Phone=d1078da587a31e1348f5b923747e6c0a71edaab39adf6a289f67ee32586c3b17,
OID.2.5.4.65=3eoyz5fdi14lga7btw0px8s629vjhcrk, T=0456, O=Personal, C=IN
Date:30-04-2026 15:59:16 +05:30

Chirag Thummar
Managing Director
DIN: 10640822